Related Experiment Video
Updated: Dec 20, 2025
Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
Published on: January 7, 2013
Cysteine Cathepsins Inhibition Affects Their Expression and Human Renal Cancer Cell Phenotype
Magdalena Rudzińska1, Alessandro Parodi1, Valentina D Maslova2
1Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Abstract:
Renal cancer would greatly benefit from new therapeutic strategies since, in advanced stages, it is refractory to classical chemotherapeutic approaches. In this context, lysosomal protease cysteine cathepsins may represent new pharmacological targets. In renal cancer, they are characterized by a higher expression, and they were shown to play a role in its aggressiveness and spreading. Traditional studies in the field were focused on understanding the therapeutic potentialities of cysteine cathepsin inhibition, while the direct impact of such therapeutics on the expression of these enzymes was often overlooked. In this work, we engineered two fluoromethyl ketone-based peptides with inhibitory activity against cathepsins to evaluate their potential anticancer activity and impact on the lysosomal compartment in human renal cancer. Molecular modeling and biochemical assays confirmed the inhibitory properties of the peptides against cysteine cathepsin B and L. Different cell biology experiments demonstrated that the peptides could affect renal cancer cell migration and organization in colonies and spheroids, while increasing their adhesion to biological substrates. Finally, these peptide inhibitors modulated the expression of LAMP1, enhanced the expression of E-cadherin, and altered cathepsin expression. In conclusion, the inhibition of cysteine cathepsins by the peptides was beneficial in terms of cancer aggressiveness; however, they could affect the overall expression of these proteases.
Insights
New peptide inhibitors targeting cysteine cathepsins show promise for treating advanced renal cancer by reducing cell migration and enhancing adhesion. However, these inhibitors also impact the overall expression of these key proteases.
Area of Science:
- Oncology
- Biochemistry
Background:
- Advanced renal cancer is difficult to treat with traditional chemotherapy.
- Lysosomal proteases, specifically cysteine cathepsins, are upregulated in renal cancer and linked to its aggressiveness.
- Targeting cysteine cathepsins offers a potential therapeutic strategy, but their impact on enzyme expression needs further investigation.
Purpose of the Study:
- To engineer and evaluate novel fluoromethyl ketone-based peptide inhibitors against cysteine cathepsins in human renal cancer.
- To assess the anticancer activity and effects on the lysosomal compartment of these peptide inhibitors.
- To investigate the impact of cathepsin inhibition on renal cancer cell behavior and protease expression.
Main Methods:
- Molecular modeling and biochemical assays to confirm peptide inhibitory activity against cathepsin B and L.
- Cell biology experiments to assess effects on cell migration, colony/spheroid organization, and adhesion.
- Analysis of lysosomal-associated membrane protein 1 (LAMP1), E-cadherin, and cathepsin expression.
Main Results:
- Peptides demonstrated confirmed inhibitory activity against cysteine cathepsin B and L.
- Inhibitors affected renal cancer cell migration and organization, while increasing cell adhesion.
- Peptide treatment modulated LAMP1 and E-cadherin expression and altered cathepsin expression levels.
Conclusions:
- Fluoromethyl ketone-based peptide inhibitors show potential in reducing renal cancer aggressiveness by inhibiting cysteine cathepsins.
- These inhibitors impact cellular behavior and adhesion, suggesting therapeutic benefits.
- The study highlights that cathepsin inhibition can alter the overall expression of these proteases, warranting further research.
